In a clinical study, MYP administration for 3 months in severe ME/CFS patients significantly changed the pain range, results of a questionnaire for evaluating fatigue, and related biomarkers. The gene discussed is NOL3; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.